naproxen

(redirected from Vimovo)
Also found in: Dictionary, Thesaurus, Medical.

naproxen

and

naproxen sodium,

potent nonsteroidal anti-inflammatory drugs (NSAID) used to alleviate the minor pain of arthritis, menstruation, headaches, and the like, and to reduce fever. Along with ibuprofenibuprofen
, nonsteroidal anti-inflammatory drug (NSAID) that reduces pain, fever, and inflammation. Along with naproxen and ketoprofen, ibuprofen belongs to the propionic acid class of NSAIDs. It was first made available in 1967.
..... Click the link for more information.
 and ketoprofenketoprofen
, nonsteroidal anti-inflammatory drug (NSAID) with anti-inflammatory, analgesic, and fever-reducing effects, used to relieve the symptoms of headaches, arthritis, and painful menstruation.
..... Click the link for more information.
, they belong to the propionic acid class of NSAIDs. They have been available as prescription drugs for arthritis from 1976. Naproxen sodium was approved at a low dosage as an over-the-counter painkiller in the United States in 1994; it was first marketed under the tradename Aleve. Side effects may include gastrointestinal distress and dizziness, and renal impairment has been reported in some instances with long-term use. The drugs should not be used by those who are allergic to aspirinaspirin,
acetyl derivative of salicylic acid (see salicylate) that is used to lower fever, relieve pain, reduce inflammation, and thin the blood. Common conditions treated with aspirin include headache, muscle and joint pain, and the inflammation caused by rheumatic fever and
..... Click the link for more information.
.
References in periodicals archive ?
The $13.1 millionincrease in adjusted total revenue in the current quarter was primarily related to the timing of the Aralez Transaction, which provided an incremental $9.7 million of total revenue contributed from the Commercial Business segment and $4.7 million attributable to the Vimovo royalties related to the U.S.
Vimovo is a modified-release fixed-dose combination tablet of naproxen, a pain -relieving NSAID and esomeprazole, the active ingredient in Nexium, for the treatment of various inflammatory diseases, including osteoarthritis, rheumatoid arthritis and ankylosing spondylitis in patients at risk of developing NSAID (non-steroidal anti -inflammatory drugs) associated gastric ulcers and/or duodenal ulcers.
Vimovo, co-developed by US-based pharma company Pozen and Anglo-Swedish major AstraZeneca, is a fixed-dose combination of a delayed-release form of pain reliever naproxen and stomach acid-reducing drug Nexium.
(Nuvo or the Company) (TSX: NRI; OTCQX: NRIFF), a Canadian-focused healthcare company with global reach and a diversified portfolio of commercial products, today provided an update regarding its VIMOVO patents.
German pharmaceutical company Grunenthal said on Monday that it has agreed to acquire AstraZeneca's European rights to Nexium and the global (ex US and Japan) rights to Vimovo for a total consideration of up to USD922m (EUR811m) subject to approval from the relevant antitrust authorities.
In the next few weeks, Pozen will transfer ownership of the investigational new drug (IND) application and the new drug application (NDA) for Vimovo to AstraZeneca.
Aralez announced that it intends to enter into purchase agreements with two separate stalking-horse purchasers to sell its main operating businesses: an agreement to sell its Vimovo royalties and Canadian operations to Nuvo Pharmaceuticals in a transaction valued at $110M and an agreement to sell its Toprol-XL franchise to its secured lender, certain funds managed by Deerfield Management, in a transaction valued at $140M.
risk of of low-dose aspirin-associated peptic ulcers), but Vimovo, a
3 May 2010 - Swedish pharma major AstraZeneca (LON: AZN) (STO: AZN) and its US partner Pozen Inc (NASDAQ: POZN) said late last Friday that the US Food and Drug Administration (FDA) had approved their co-developed arthritis tablet Vimovo.
The company intends to sell its VIMOVO royalties and Canadian operations to Nuvo Pharmaceuticals, in a deal valued at USD110m and to sell its TOPROL-XL Franchise to its secured lender, certain funds managed by Deerfield Management Company LP, in a transaction valued at USD140m.
This strategic direction will involve (i) a focus on the company's strong Canadian business, supported by Toprol-XL and its authorized generic as well as Vimovo royalties, and (ii) the discontinuation of the remaining U.S.
AstraZeneca and Pozen received approval from the FDA for Vimovo (naproxen and esomeprazole magnesium) delayed-release tablets for the relief of symptoms of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis, and to decrease the risk of gastric ulcers in patients at risk of developing NSAID-associated gastric ulcers.